

---

**Product Data Sheet**

---

Product Name: DDP-38003 dihydrochloride

Cat. No.: GC33013

**Chemical Properties**

Cas. No. 1831167-98-6

SMILES [H]Cl.O=C(NC1=CC=C([C@@H]2C[C@H]2N)C=C1)C(C=C3)=CC=C3N4CCN(C)CC4.[H]ClFormula C<sub>21</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O M.Wt 423.38

Solubility DMSO : ≥ 29 mg/mL (68.50 mM) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT Condition , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Mice: CD-1 mice is used in the study. DDP-38003 is dissolved (40% PEG 400 in a 5% glucose solution) and orally administered 3 days per week (Monday, Tuesday and Wednesday) for 3 weeks at the doses of 11.25 mg/kg and 22.5 mg/kg. The treatment started once blast cells are detected in the recipients' peripheral blood (10 days after cell injection). The survival of mice of the different experimental groups is analyzed and represented by a Kaplan-Meier survival plot[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1]. Vianello P, et al.  
Discovery of a Novel  
Inhibitor of Histone  
Lysine-Specific  
Demethylase 1A  
(KDM1A/LSD1) as Orally  
Active Antitumor Agent. J  
Med Chem. 2016 Feb  
25;59(4):1501-17.

### Background

DDP-38003 dihydrochloride is a novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC<sub>50</sub> of 84 nM.

DDP-38003 inhibits KDM1A with an IC<sub>50</sub> of 84 nM. DDP-38003 is more active in reducing the colony forming ability and in inducing the differentiation of THP-1 cells compared to the 1R, 2S analogue[1].

DDP-38003 exhibits in vivo efficacy after oral administration, determining a 62% increased survival in mouse leukemia models with evidence of KDM1A inhibition. The half life of DDP-38003 is 8 h. A significant dose dependent increase of mice survival is obtained by DDP-38003 treatment. The survival rate increases 35% and 62% at the dose of 11.25 and 22.50 mg/kg, respectively. DDP-38003 is a potential oral anticancer agent[1].

[1]. Vianello P, et al. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. J Med Chem. 2016 Feb 25;59(4):1501-17.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA